The complaint accuses the defendants of designing and operating addictive platforms that harm children's mental health and ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

That busy highway could be contributing to depression, and not just because you’re snarled in a traffic jam.Air pollut ...

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

A new study published in Psychological Medicine sheds light on how specific depression symptoms are related to decisions ...

People with bipolar I disorder have had at least one manic episode preceded or followed by hypomanic or major depressive ...

YORK, Pa. — Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance to help some people treat depression. The Federal Drug ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...